Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)

Got To Article
Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and above with relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukemia (ALL).
0 comments

EV Mobility and Autonomy Team Up to Accelerate Flexible Access to Electric Vehicles

Got To Article
Autonomy™, the nation’s largest electric vehicle subscription company has partnered with EV Mobility, LLC., the leading all-electric vehicle car-sharing platform. EV Mobility provides electric vehicles on demand 24/7 as an amenity to luxury hotels,
0 comments